Ericka M Ebot (Ericka Ebot)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 9

Top Topics

Benign Prostatic Hyperplasia

Radical Prostatectomy

Gene Expression

Top Venues

NPJ genomic medicine

Molecular cancer research : MCR

Cancer causes & control : CCC

This page only lists publications with an associated author ORCID identifier.

Publications

Debra L Richardson, Julia Coelho França Quintanilha, Natalie Danziger, Gerald Li, Ethan S Sokol, Alexa B Schrock, Ericka M Ebot, Neeru Bhardwaj, Tanesha Norris, Anosheh Afghahi, Anthony Frachioni, Christina R Washington, Lauren Dockery, Julia A Elvin, Ryon P Graf, Kathleen M Moore
Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1/2 and a scar-based HRD signature in real-world practice. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Radwa Sharaf, Dexter X Jin, John Grady, Christine Napier, Ericka M Ebot, Garrett M Frampton, Lee A Albacker, David M Thomas, Meagan Montesion
A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content. NPJ genomic medicine 8 (1) (2023)
Smruthy S Sivakumar, Jay A Moore, Meagan Montesion, Radwa Sharaf, Douglas I Lin, Caterina I Colón, Zoe Fleischmann, Ericka M Ebot, Justin Y Newberg, Jennifer M Mills, Priti S Hegde, Quintin Pan, Afshin Dowlati, Garrett M Frampton, Julien Sage, Christine M Lovly
Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation. Cancer discovery (2023)
Jie He, Natallia Kalinava, Parul Doshi, Dean C Pavlick, Lee A Albacker, Ericka M Ebot, Hanna Tukachinsky, James Pratt, Gina Fusaro, Geoffrey R Oxnard, George Green, David Fabrizio, Jonathan Baden
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB. Journal for immunotherapy of cancer 11 (11) (2023)
Ericka M Ebot, Daniel L Duncan, Khaled Tolba, David Fabrizio, Garrett M Frampton, Leah A Comment, Lee A Albacker
Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy. NPJ precision oncology 6 (1) (2022)
Konrad H Stopsack, Xiaofeng A Su, J Bailey Vaselkiv, Rebecca E Graff, Ericka M Ebot, Andreas Pettersson, Rosina T Lis, Michelangelo Fiorentino, Massimo Loda, Kathryn L Penney, Tamara L Lotan, Lorelei A Mucci
Transcriptomes of prostate cancer with TMPRSS2:ERG and other ETS fusions. Molecular cancer research : MCR (2022)
Konrad H Stopsack, Ericka M Ebot, Mary Kathryn Downer, Travis A Gerke, Jennifer R Rider, Philip W Kantoff, Lorelei A Mucci
Regular aspirin use and gene expression profiles in prostate cancer patients. Cancer causes & control : CCC 29 (8) (2018)
Sabrina H Tsang, Samuel F Peisch, Brendan Rowan, Sarah C Markt, Amparo G Gonzalez-Feliciano, Siobhan Sutcliffe, Elizabeth A Platz, Lorelei A Mucci, Ericka M Ebot
Association between Trichomonas vaginalis and prostate cancer mortality. International journal of cancer 144 (10) (2018)
Ericka M Ebot, Travis Gerke, David P Labbé, Jennifer A Sinnott, Giorgia Zadra, Jennifer R Rider, Svitlana Tyekucheva, Kathryn M Wilson, Rachel S Kelly, Irene M Shui, Massimo Loda, Philip W Kantoff, Stephen Finn, Matthew G Vander Heiden, Myles Brown, Edward L Giovannucci, Lorelei A Mucci
Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. Cancer 123 (21) (2017)